169 related articles for article (PubMed ID: 33928568)
21. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.
Zhou J; Tiemann K; Chomchan P; Alluin J; Swiderski P; Burnett J; Zhang X; Forman S; Chen R; Rossi J
Nucleic Acids Res; 2013 Apr; 41(7):4266-83. PubMed ID: 23470998
[TBL] [Abstract][Full Text] [Related]
22. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
23. Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma.
Delač M; Motaln H; Ulrich H; Lah TT
Cytometry A; 2015 Sep; 87(9):806-16. PubMed ID: 26189784
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA.
Zhu Q; Shibata T; Kabashima T; Kai M
Eur J Med Chem; 2012 Oct; 56():396-9. PubMed ID: 22907035
[TBL] [Abstract][Full Text] [Related]
25. Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.
Dhanya CR; Mary AS; Madhavan M
Chem Biol Drug Des; 2023 May; 101(5):1162-1180. PubMed ID: 36099164
[TBL] [Abstract][Full Text] [Related]
26. Photomodulating Gene Expression by Using Caged siRNAs with Single-Aptamer Modification.
Zhang L; Chen C; Fan X; Tang X
Chembiochem; 2018 Jun; 19(12):1259-1263. PubMed ID: 29488297
[TBL] [Abstract][Full Text] [Related]
27. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
[TBL] [Abstract][Full Text] [Related]
28. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
29. A universal protein tag for delivery of SiRNA-aptamer chimeras.
Liu HY; Gao X
Sci Rep; 2013 Nov; 3():3129. PubMed ID: 24196104
[TBL] [Abstract][Full Text] [Related]
30. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.
Subramanian N; Kanwar JR; Athalya PK; Janakiraman N; Khetan V; Kanwar RK; Eluchuri S; Krishnakumar S
J Biomed Sci; 2015 Jan; 22():4. PubMed ID: 25576037
[TBL] [Abstract][Full Text] [Related]
31. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells.
Esposito CL; Nuzzo S; Kumar SA; Rienzo A; Lawrence CL; Pallini R; Shaw L; Alder JE; Ricci-Vitiani L; Catuogno S; de Franciscis V
J Control Release; 2016 Sep; 238():43-57. PubMed ID: 27448441
[TBL] [Abstract][Full Text] [Related]
32. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
[TBL] [Abstract][Full Text] [Related]
33. Aptamer mediated siRNA delivery.
Chu TC; Twu KY; Ellington AD; Levy M
Nucleic Acids Res; 2006 Jun; 34(10):e73. PubMed ID: 16740739
[TBL] [Abstract][Full Text] [Related]
34. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
35. TRIM8 regulates stemness in glioblastoma through PIAS3-STAT3.
Zhang C; Mukherjee S; Tucker-Burden C; Ross JL; Chau MJ; Kong J; Brat DJ
Mol Oncol; 2017 Mar; 11(3):280-294. PubMed ID: 28100038
[TBL] [Abstract][Full Text] [Related]
36. Method for Confirming Cytoplasmic Delivery of RNA Aptamers.
Dickey DD; Thomas GS; Dassie JP; Giangrande PH
Methods Mol Biol; 2016; 1364():209-17. PubMed ID: 26472453
[TBL] [Abstract][Full Text] [Related]
37. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
[TBL] [Abstract][Full Text] [Related]
38. Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP; Giangrande PH
Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
Zhou J; Rossi JJ
BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
[TBL] [Abstract][Full Text] [Related]
40. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
